FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2523854686> ?p ?o ?g. }

• W2523854686 abstract "Abstract Introduction: Ponatinib, a potent oral tyrosine kinase inhibitor (TKI), is approved for use in patients with refractory CML and Ph+ ALL, including patients with the BCR-ABLT315I mutation. This post hoc analysis was undertaken to assess the evolution of the efficacy and safety of ponatinib over time in CP-CML patients in the ongoing phase 2 PACE trial (NCT01207440). Updated data with 4 years of follow-up, including an analysis of the management of select adverse events (AEs), will be presented. Methods: Patients with CML/Ph+ ALL who were resistant or intolerant to dasatinib or nilotinib or who had the T315I mutation (N=449) were enrolled and treated with ponatinib (starting dose 45 mg once daily). Accumulation of arterial occlusive events (AOEs) in the ponatinib program led to recommendations for dose reduction in PACE in October 2013. Efficacy and safety among CP-CML patients are reported as of February 2, 2015 in this abstract. Results: Included in the analysis were 270 CP-CML patients who received treatment, with a median follow-up of 42 (0.1-52.5) months. At the time of analysis, 42% of CP-CML patients (114/270) continued to receive ponatinib. Primary reasons for discontinuation were AEs (18%), withdrawal by patient (11%), and disease progression (10%). Characteristics of CP-CML patients continuing to receive ponatinib were similar to those of the overall cohort (Table 1). Of 267 CP-CML patients analyzed for efficacy, 59% and 53% achieved MCyR and CCyR at any time, and 39% and 23% achieved at least MMR and MR4.5, respectively; despite dose reductions from 45 mg/d at baseline, responses continued to deepen after the first year (Table 2). The probability of maintaining MCyR at 3 years was 83%, and the estimated PFS/OS rates were 60%/81% at 3 years. AEs in ≥20% of CP-CML patients were rash (46%), abdominal pain (46%), thrombocytopenia (45%), headache (43%), dry skin (41%), constipation (41%), hypertension (33%), arthralgia (32%), fatigue (30%), nausea (27%), increased lipase (26%), pyrexia (26%), myalgia (24%), pain in an extremity (21%), and back pain (20%). Most newly occurring AEs were observed within the first year. Rates of AOEs (any/serious) were 28%/23%, including cardiovascular (14%/11%), cerebrovascular (11%/9%), and peripheral vascular (11%/8%) events; median time to onset for AOEs was 14.1 (0.3-44.0) months. Exposure-adjusted incidence rates of new AOEs (events per 100 patient-years) have appeared to remain approximately stable or decrease over time; rates were 14.3 in Year 1, 15.2 in Year 2, 11.7 in Year 3, and 9.9 in Year 4 (analysis for Year 4 does not yet cover a full fourth year for all CP-CML patients). Conclusions: With longer follow-up in the PACE trial, the benefit/risk profile of ponatinib continues to evolve and remains favorable for many patients in this trial. In this analysis, the baseline characteristics of patients remaining on study did not differ substantially across the time points examined. Despite a decline from initial dose intensity, deep and lasting responses have continued to be observed after the first year in this trial of heavily pretreated patients. Most AEs have occurred early in treatment; AOEs have typically had a later onset-exposure-adjusted incidence rates of AOEs have not increased over time. Table 1. Characteristics of CP-CML Patients Continuing to Receive Ponatinib Over Time Baseline (n=270) Patients Receiving Ponatinib at 1 Year (n=179) Patients Receiving Ponatinib at 2 Years (n=156) Patients Receiving Ponatinib at 3 Years (n=125) Median age at baseline, years 60 58 58 58 ≥2 prior TKIs at baseline, % 93 91 92 92 ≥3 prior TKIs at baseline, % 60 55 54 54 Median time from diagnosis to first dose, years 7.0 6.9 7.0 6.7 Median dose intensity, mg/d 45.0 29.1 29.0 28.8 Mutations detected at baseline, % 49 49 48 47 T315I mutation detected at baseline, % 24 25 23 22 Table 2. Cumulative Response Rates in CP-CML Patients Receiving Ponatinib Over Time (n=267) By 1 Year, % By 2 Years, % By 3 Years, % Total, % MCyR 55 58 59 59 CCyR 50 53 53 53 MMR 30 36 39 39 MR4.5 9 16 22 23 Disclosures Cortes: Pfizer: Consultancy, Research Funding; BMS: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; ARIAD Pharmaceuticals Inc.: Consultancy, Research Funding; Teva: Consultancy, Research Funding. Pinilla-Ibarz:Pfizer: Consultancy, Other: Consulting & Advisory Role, Research Funding, Speakers Bureau; Novartis: Consultancy, Other: Consulting & Advisory Role, Research Funding; Teva: Consultancy, Speakers Bureau; ARIAD Pharmaceuticals, Inc.: Consultancy, Other: Consulting & Advisory Role, Research Funding; BMS: Consultancy, Honoraria, Other: Consulting & Advisory Role, Speakers Bureau. le Coutre:Novartis: Honoraria; ARIAD Pharmaceuticals Inc.: Honoraria; BMS: Honoraria; Pfizer: Honoraria. Paquette:ARIAD Pharmaceuticals, Inc.: Honoraria, Speakers Bureau; BMS: Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau; Incyte: Honoraria, Speakers Bureau; Astra-Zeneca: Consultancy. Chuah:Children International: Honoraria; Novartis: Honoraria; Bristol Meyers Squibb: Honoraria. Nicolini:Ariad Pharmaceuticals: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Apperley:BMS: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ARIAD: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Talpaz:Pfizer: Consultancy, Other: Travel/Expenses, Research Funding; Novartis: Consultancy, Other: Travel/Expenses, Research Funding; ARIAD Pharmaceuticals, Inc.: Consultancy, Other: Travel/Expenses, Research Funding; Sanofi: Research Funding; Incyte: Other: Travel/Expenses, Research Funding. DeAngelo:Incyte: Consultancy; Novartis: Consultancy; Bristol Myers Squibb: Consultancy; Pfizer: Consultancy; Celgene: Consultancy; Ariad: Consultancy; Agios: Consultancy; Amgen: Consultancy. Abruzzese:Pfizer: Other: Consulting or Advisory Role; Novartis: Other: Consulting or Advisory Role; BMS: Other: Consulting or Advisory Role; ARIAD Pharmaceuticals Inc.: Other: Consulting & Advisory Role. Rea:Bristol-Myers Squibb: Honoraria; Novartis: Honoraria; Pfizer: Honoraria; Ariad: Honoraria. Baccarani:NOVARTIS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ARIAD Pharmaceuticals, Inc.: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; PFIZER: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Müller:BMS: Honoraria, Other: Consulting or Advisory Role, Research Funding; Novartis: Honoraria, Other: CONSULTING OR ADVISORY ROLE, Research Funding; ARIAD Pharmaceuticals Inc.: Honoraria, Other: Consulting & Advisory Role, Research Funding. Lustgarten:ARIAD Pharmaceuticals Inc.: Employment, Equity Ownership, Other: Stock. Conlan:ARIAD Pharmaceuticals Inc.: Other: Stock. Guilhot:Novartis: Honoraria, Other: TRAVEL, ACCOMODATIONS, EXPENSES; Pfizer: Honoraria; Celgene: Consultancy, Other: CONSULTING OR ADVISORY ROLE. Deininger:BMS: Consultancy, Honoraria, Other: Consulting & Advisory Role, Research Funding; Novartis: Consultancy, Honoraria, Other: Consulting or Advisory Role, Research Funding; Celgene: Research Funding; Gilead: Research Funding; ARIAD Pharmaceutical Inc.: Consultancy, Honoraria, Other: Consulting or Advisory Role; Pfizer: Consultancy, Honoraria, Other: Consulting or Advisory Role; Incyte: Consultancy, Honoraria, Other: Consulting or Advisory Role. Hochhaus:Bristol-Myers Squibb: Honoraria, Research Funding; ARIAD: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Pfizer: Honoraria, Research Funding. Hughes:ARIAD: Honoraria, Research Funding; Bristol-Myers Squibb: Honoraria, Research Funding; Novartis: Honoraria, Research Funding. Kantarjian:Novartis: Research Funding; BMS: Research Funding; Pfizer: Research Funding; Amgen: Research Funding. Shah:ARIAD Pharmaceuticals, Inc.: Research Funding; Bristol-Myers Squibb: Research Funding; Pfizer: Research Funding; Plexxikon: Research Funding; Daiichi-Sankyo: Research Funding." @default.
• W2523854686 created "2016-10-07" @default.
• W2523854686 creator A5006302059 @default.
• W2523854686 creator A5011529063 @default.
• W2523854686 creator A5015101485 @default.
• W2523854686 creator A5015115182 @default.
• W2523854686 creator A5015214215 @default.
• W2523854686 creator A5028793559 @default.
• W2523854686 creator A5029315909 @default.
• W2523854686 creator A5031805513 @default.
• W2523854686 creator A5035964802 @default.
• W2523854686 creator A5036874214 @default.
• W2523854686 creator A5038563211 @default.
• W2523854686 creator A5044224344 @default.
• W2523854686 creator A5049971021 @default.
• W2523854686 creator A5052875031 @default.
• W2523854686 creator A5055797334 @default.
• W2523854686 creator A5060360947 @default.
• W2523854686 creator A5061902084 @default.
• W2523854686 creator A5074115908 @default.
• W2523854686 creator A5078535679 @default.
• W2523854686 creator A5082189560 @default.
• W2523854686 creator A5082924494 @default.
• W2523854686 creator A5087589346 @default.
• W2523854686 creator A5088450042 @default.
• W2523854686 creator A5090435894 @default.
• W2523854686 date "2015-12-03" @default.
• W2523854686 modified "2023-10-15" @default.
• W2523854686 title "Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study" @default.
• W2523854686 doi "https://doi.org/10.1182/blood.v126.23.5142.5142" @default.
• W2523854686 hasPublicationYear "2015" @default.
• W2523854686 type Work @default.
• W2523854686 sameAs 2523854686 @default.
• W2523854686 citedByCount "0" @default.
• W2523854686 crossrefType "journal-article" @default.
• W2523854686 hasAuthorship W2523854686A5006302059 @default.
• W2523854686 hasAuthorship W2523854686A5011529063 @default.
• W2523854686 hasAuthorship W2523854686A5015101485 @default.
• W2523854686 hasAuthorship W2523854686A5015115182 @default.
• W2523854686 hasAuthorship W2523854686A5015214215 @default.
• W2523854686 hasAuthorship W2523854686A5028793559 @default.
• W2523854686 hasAuthorship W2523854686A5029315909 @default.
• W2523854686 hasAuthorship W2523854686A5031805513 @default.
• W2523854686 hasAuthorship W2523854686A5035964802 @default.
• W2523854686 hasAuthorship W2523854686A5036874214 @default.
• W2523854686 hasAuthorship W2523854686A5038563211 @default.
• W2523854686 hasAuthorship W2523854686A5044224344 @default.
• W2523854686 hasAuthorship W2523854686A5049971021 @default.
• W2523854686 hasAuthorship W2523854686A5052875031 @default.
• W2523854686 hasAuthorship W2523854686A5055797334 @default.
• W2523854686 hasAuthorship W2523854686A5060360947 @default.
• W2523854686 hasAuthorship W2523854686A5061902084 @default.
• W2523854686 hasAuthorship W2523854686A5074115908 @default.
• W2523854686 hasAuthorship W2523854686A5078535679 @default.
• W2523854686 hasAuthorship W2523854686A5082189560 @default.
• W2523854686 hasAuthorship W2523854686A5082924494 @default.
• W2523854686 hasAuthorship W2523854686A5087589346 @default.
• W2523854686 hasAuthorship W2523854686A5088450042 @default.
• W2523854686 hasAuthorship W2523854686A5090435894 @default.
• W2523854686 hasConcept C126322002 @default.
• W2523854686 hasConcept C143998085 @default.
• W2523854686 hasConcept C187212893 @default.
• W2523854686 hasConcept C2777583451 @default.
• W2523854686 hasConcept C2778729363 @default.
• W2523854686 hasConcept C2779536868 @default.
• W2523854686 hasConcept C2780381907 @default.
• W2523854686 hasConcept C71924100 @default.
• W2523854686 hasConceptScore W2523854686C126322002 @default.
• W2523854686 hasConceptScore W2523854686C143998085 @default.
• W2523854686 hasConceptScore W2523854686C187212893 @default.
• W2523854686 hasConceptScore W2523854686C2777583451 @default.
• W2523854686 hasConceptScore W2523854686C2778729363 @default.
• W2523854686 hasConceptScore W2523854686C2779536868 @default.
• W2523854686 hasConceptScore W2523854686C2780381907 @default.
• W2523854686 hasConceptScore W2523854686C71924100 @default.
• W2523854686 hasLocation W25238546861 @default.
• W2523854686 hasOpenAccess W2523854686 @default.
• W2523854686 hasPrimaryLocation W25238546861 @default.
• W2523854686 hasRelatedWork W2342469096 @default.
• W2523854686 hasRelatedWork W2530440549 @default.
• W2523854686 hasRelatedWork W2559685064 @default.
• W2523854686 hasRelatedWork W2562981062 @default.
• W2523854686 hasRelatedWork W2612511582 @default.
• W2523854686 hasRelatedWork W2784823232 @default.
• W2523854686 hasRelatedWork W2785134906 @default.
• W2523854686 hasRelatedWork W2903843213 @default.
• W2523854686 hasRelatedWork W2905649019 @default.
• W2523854686 hasRelatedWork W2906700714 @default.
• W2523854686 hasRelatedWork W2906862520 @default.
• W2523854686 hasRelatedWork W2906983378 @default.
• W2523854686 hasRelatedWork W2908676058 @default.
• W2523854686 hasRelatedWork W2914497255 @default.
• W2523854686 hasRelatedWork W2927166793 @default.
• W2523854686 hasRelatedWork W2978352165 @default.
• W2523854686 hasRelatedWork W2989442874 @default.
• W2523854686 hasRelatedWork W3095806280 @default.
• W2523854686 hasRelatedWork W3096011506 @default.
• W2523854686 hasRelatedWork W3174444513 @default.
• W2523854686 isParatext "false" @default.
• W2523854686 isRetracted "false" @default.

• next